Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Earnings for Ipsen S.A. (IPN.PA)
Earnings in 2023 (TTM): $821.71 M
According to Ipsen S.A.'s latest financial reports the company's current earnings (TTM) are $821.71 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Ipsen S.A.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $821.71 M | $700.32 M |
| 2022 | $765.52 M | $704.88 M |
| 2021 | $858.01 M | $702.71 M |
| 2020 | $577.19 M | $595.55 M |
| 2019 | $-37,819,718 | $-59,663,865 |
| 2018 | $538.17 M | $423.3 M |
| 2017 | $404.28 M | $295.93 M |
| 2016 | $325.92 M | $245.5 M |
| 2015 | $260.93 M | $206.38 M |
| 2014 | $226.37 M | $166.82 M |
| 2013 | $218.98 M | $165.78 M |
| 2012 | $130.69 M | $-32,050,037 |
| 2011 | $44.96 M | $460.79 K |
| 2010 | $136.28 M | $103.98 M |
| 2009 | $181.82 M | $170.8 M |
| 2008 | $196.88 M | $160.48 M |
| 2007 | $224.81 M | $164.18 M |
| 2006 | $201.79 M | $156.5 M |
| 2005 | $168.46 M | $129.58 M |
| 2004 | $125.68 M | $90.2 M |